Phase Ib multicenter study of anti-TIM-3 (S095018/Sym023) in combination with anti-PD-1 (Sym021) in patients with advanced/metastatic recurrent biliary tract cancer

Background
T-cell immunoglobulin and mucin-domain containing 3 (TIM-3) is an inhibitory receptor linked to decreased antitumor activity of immune cells. S095018 is a human anti-TIM-3 IgG2 antibody that blocks the binding of phosphatidyl serine to TIM-…

Role of solute carrier family 7 member 7 in cancer: opportunities for tumor microenvironment research

Cancer poses serious health risks to humans. The solute carrier (SLC) family is crucial for cancer development regulation. As a member of this family, SLC7A7 forms a heterodimer with SLC3A2 to transport cationic and neutral amino acids (AA) across the…

Evaluation of mixed response in tumor size and survival in patients with rare cancers treated with dual checkpoint inhibitor therapy (DART SWOG S1609)

Background
Mixed response, where different lesions within the same patient show discordant responses to treatment, remains poorly understood. To better understand the complex effects of mixed response on patient survival, we devised three different de…

Complement system in cancer: friend or foe of immunotherapy

The complement system, a key component of the immune response, plays a dual role in cancer, influencing both tumor suppression and progression. Its three activation pathways (classical, alternative, and lectin) initiate immune processes, including ops…

Dual regulation of CXCR6+CD8+ T cells modulates cytotoxic and exhaustion-associated programs during prostate cancer progression

Background
Prostate cancer (PCa) is widely recognized as an immunologically “cold” tumor, characterized by a paucity of effector T cells and a limited response to immune checkpoint blockade therapy. Although the chemokine receptor CXCR6 has been ident…

CD79A/CD40 intracellular domain uses a 4-1BB-like metabolic pathway driven by cholesterol biosynthesis

Background
Chimeric antigen receptor (CAR)-T cell therapy targeting CD19 has transformed the treatment of hematologic malignancies. The costimulatory domain (CSD) of CAR constructs plays a crucial role in determining T cell metabolism, persistence, an…

Clinical application prospects of Nectin-4 in pan-cancer: an analysis based on the Trialtrove database

This research analyzes the global landscape of clinical trials focusing on therapies targeting the Nectin cell adhesion molecule 4 (Nectin-4) across various malignancies, using data from the Trialtrove database. Analysis of 136 interventional trials r…

Clinical trial landscape of CAR-based cell therapy for gastrointestinal malignancies

Gastrointestinal malignancies (GIM) impose a substantial global health burden, accounting for approximately 33% of cancer-related mortality worldwide. Although chimeric antigen receptor (CAR)-based cell therapy has achieved remarkable success in hemat…

AGPAT3 reshapes tumor cell vulnerability to IFN{gamma}-mediated ferroptosis and enhances immunotherapy efficacy through lipid remodeling

Background
Ferroptosis plays a critical role in immune regulation and tumor microenvironment remodeling. However, its therapeutic potential in enhancing immune checkpoint inhibitor (ICI) efficacy remains incompletely understood and warrants further in…

deneme bonusu veren siteler - canlı bahis siteleri - casino siteleri casino siteleri deneme bonusu veren siteler canlı casino siteleri error code: 520